Emmaus Life Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EMMA research report →
About the company
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations.
- CEO
- Willis C. Lee
- IPO
- 2000
- Employees
- 34
- HQ
- Torrance, CA, US
Price Chart
- Market Cap
- $761.54K
- P/E
- -0.08
- P/S
- 0.06
- P/B
- -0.01
- EV/EBITDA
- -597.12
- Div Yield
- 0.00%
- Gross Margin
- 93.35%
- Op Margin
- 3.22%
- Net Margin
- -70.65%
- ROE
- 13.78%
- ROIC
- -1.67%
- Revenue
- $12.45M · -25.22%
- Net Income
- $-7,492,000 · -16.10%
- EPS
- $-0.12 · -20.00%
- Op Income
- $231.00K
- FCF YoY
- 99.48%
- 52W High
- $0.02
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 8.86
- Avg Volume
- 57.13K
Get TickerSpark's AI analysis on EMMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | DU HENRY HUY | other | 0 |
| Oct 1, 24 | Kuwahara Jon | other | 0 |
| Sep 16, 24 | Lim Seah H. | buy | 20,000 |
| Feb 29, 24 | LEE WILLIS C | buy | 77,000 |
| Feb 28, 24 | LEE WILLIS C | buy | 15,000 |
| Feb 27, 24 | LEE WILLIS C | buy | 10,000 |
| Feb 26, 24 | LEE WILLIS C | buy | 13,200 |
| Feb 1, 24 | Zwicker Ian Harvey | other | 100,000 |
| Feb 1, 24 | ZEN Wei Peu | other | 100,000 |
| Feb 1, 24 | Lim Seah H. | other | 100,000 |
Our EMMA coverage
Recent articles, reports, and earnings notes.
No research on EMMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EMMA report →Similar companies
Peers in the same neighborhood.